intravenous administration of ACMP

PreclinicalSmall molecule

intravenous administration of ACMP is one of 14 small molecule programs targeting Facial Pain. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Facial PainActive, not recruiting

Facial PainPreclinical

Active, not recruiting

Competition

Competitive Landscape

13 competitors in Facial Pain

#DrugCompanyPhaseTrials

Aimovig

Amgen

Approved

1 2

Lexapro

AbbVie

Approved

1 3

Decadron

AAspen Global Incorporated

Approved

1 4

Kenalog

BBassett Healthcare

Approved

1 5

Marcaine

IInnocoll

Approved

1 6

Celebrex

PPhiladelphia Eye Associates

Approved

—7

Aspercreme Warming

AAveritas Pharma, Inc.

Approved

—8

Ketalar

AAultman Health Foundation

Phase 2

1 9

Xylocaine

MMEDRx USA, Inc.

Phase 2

1 10

EXPAREL

Pacira Pharmaceuticals, Inc

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Facial Pain1 trial

Treatment of Atypical Resistant Facial Pain

Enrolling by invitation·AAlenka Spindler-Vesel··NCT07250984·10 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for intravenous administration of ACMP. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — intravenous administration of ACMP compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for intravenous administration of ACMP. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Alenka Spindler-Vesel company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: AAlenka Spindler-Vesel

intravenous administration of ACMP

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Facial Pain1 trial

References

Drug Info

Quick Facts

Related News